This is a unique treatment that offers a long-term drug delivery system for the treatment of diabetic macular edema. The implant releases fluocinolone acetonide, (0.2 micrograms/day) which is a steroid that treats the inflammatory component of DME and can significantly reduce the swelling in the back of the eye. The implant is very small, less than the size of a grain of rice, and can last up to 3 years. Before ILUVIEN®, the only available long-term corticosteroid treatment lasted only 3-6 months. In addition, the small size lends itself to have minimal side effects for patients. ILUVIEN® is given in the office in a relatively quick (less than 2 minutes) and painless injection.
- https://www.diabetes.org/in-my-community/local-offices/honolulu hawaii/?referrer=https://www.google.com/
- Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. NEngl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015Feb 18. PubMed PMID: 25692915; PubMed Central PMCID: PMC4422053.
- Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic Retinopathy. Prim Care. 2015 Sep;42(3):451-64. doi: 10.1016/j.pop.2015.05.005. Review. PubMed PMID: 26319349.